Vimarsana
Biggest News Aggregation in the World

Page 14 - Appropriate Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Appropriate Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Appropriate Technology Today - Breaking & Trending Today

NCAT announces its new executive director - Vimarsana News

NCAT announces its new executive director

The National Center for Appropriate Technology’s (NCAT) Board of Directors announced it has selected Fred Bahnson to lead the organization.

Sparkman Center offers hands-on training course on global health and community development - Vimarsana News

Sparkman Center offers hands-on training course on global health and community development

An accredited school of public health in Alabama, UAB SOPH seeks to improve public health, safety, and well-being through research, education, and service.

Source: uab.edu
Wood Smoke Continues to Make Women Sick in El Salvador - Vimarsana News

Wood Smoke Continues to Make Women Sick in El Salvador

SAN LUIS LA HERRADURA, El Salvador, Jul 04 (IPS) - Using a few dry sticks as fuel, Margarita Ramos of El Salvador lit the fire in her wood stove and set about frying two fish, occasionally fanning the flame, aware that the smoke she inhaled could affect her health.

Delhi govts pitches Rs 5 lakh fine on property without rainwater harvesting - Vimarsana News

Delhi govts pitches Rs 5 lakh fine on property without rainwater harvesting

The Delhi government has proposed slapping an environmental compensation of up to Rs 5 lakh on property owners with an area of at least 100 square metres who fail to maintain a functional rainwater harvesting system.

Meningococcal NmCV-5 Vaccine is effective in 2-to-29-year-olds in Mali and Gambia - Vimarsana News

Meningococcal NmCV-5 Vaccine is effective in 2-to-29-year-olds in Mali and Gambia

Bookmark 1. In this randomized controlled trial, the NmCV-5 vaccine elicited an immune response that was noninferior to the MenACWY-D vaccine in two-to-29-year-olds in Mali and Gambia. 2. The NmCV-5 vaccine had a similar incidence of adverse events as compared to the MenACWY-D vaccine. Evidence Rating Level: 1 (Excellent) Study Rundown: The highest incidence of